An example of that is Bifidobacteria, which can modify tumour-specific T-cell induction and increase the T-cell number, thus increasing therapeutic efficacy in the tumour microenvironment in patients treated with anti-PD-L1 agents [30]. The gene discussed is CD274; the disease is neoplasm.